Global to push GA events into
skip to main content

Title: Identification of cancer protein biomarkers using proteomic techniques

The claimed invention describes methods to diagnose or aid in the diagnosis of cancer. The claimed methods are based on the identification of biomarkers which are particularly well suited to discriminate between cancer subjects and healthy subjects. These biomarkers were identified using a unique and novel screening method described herein. The biomarkers identified herein can also be used in the prognosis and monitoring of cancer. The invention comprises the use of leptin, prolactin, OPN and IGF-II for diagnosing, prognosis and monitoring of ovarian cancer.
Inventors:
; ;
Issue Date:
OSTI Identifier:
1172149
Assignee:
Yale University (New Haven, CT) CHO
Patent Number(s):
8,975,379
Application Number:
12/644,677
Contract Number:
FG02-ER63462
Resource Relation:
Patent File Date: 2009 Dec 22
Research Org:
Yale Univ., New Haven, CT (United States)
Sponsoring Org:
USDOE
Country of Publication:
United States
Language:
English
Subject:
59 BASIC BIOLOGICAL SCIENCES

Other works cited in this record:

Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer
journal, December 2003
  • Mathur, Subbi P.; Mathur, Rajesh S.; Underwood, Paul B.
  • Gynecologic Oncology, Vol. 91, Issue 3, p. 486-493
  • DOI: 10.1016/j.ygyno.2003.08.023

Osteopontin as a Potential Diagnostic Biomarker for Ovarian Cancer
journal, April 2002
  • Kim, Jae-Hoon; Skates, Steven J.; Uede, Toshimitsu
  • JAMA, Vol. 287, Issue 13, p. 1671-1679
  • DOI: 10.1001/jama.287.13.1671

Use of serum prolactin for monitoring the therapeutic response in ovarian malignancy
journal, September 1991
  • Jha, P.; Farooq, A.; Rao, D. L.
  • International Journal of Gynecology & Obstetrics, Vol. 36, Issue 1, p. 33-38
  • DOI: 10.1016/0020-7292(91)90175-5

Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma
journal, April 2003

Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma
journal, October 2004

Serum protein markers for early detection of ovarian cancer
journal, May 2005
  • Mor, G.; Visintin, I.; Lai, Y.
  • Proceedings of the National Academy of Sciences, Vol. 102, Issue 21, p. 7677-7682
  • DOI: 10.1073/pnas.0502178102

Leptin and prolactin modulate the expression of SOCS-1 in association with interleukin-6 and tumor necrosis factor-α in mammary cells: a role in differentiated secretory epithelium
journal, September 2004

Serum tumor markers in colorectal cancer staging, grading, and follow-up
journal, August 1996

Multiplexed protein profiling on microarrays by rolling-circle amplification
journal, April 2002
  • Schweitzer, Barry; Roberts, Scott; Grimwade, Brian
  • Nature Biotechnology, Vol. 20, Issue 4, p. 359-365
  • DOI: 10.1038/nbt0402-359

Cancer screening in a high risk population: a clinical trial
journal, April 2001

Ovarian cancer screening
journal, August 2003
  • Urban, Nicole; McIntosh, Martin W.; Andersen, Marin (Robyn)
  • Hematology/Oncology Clinics of North America, Vol. 17, Issue 4, p. 989-1005
  • DOI: 10.1016/S0889-8588(03)00063-7

The role of Osteopontin in tumor metastasis
journal, October 2004

Differential Gene Expression in Chemically Induced Mouse Lung Adenomas
journal, January 2003

Ovarian dysgerminoma showing high serum levels and positive immunostaining of placental alkaline phosphatase and neuron-specific enolase associated with elevation of serum prolactin level
journal, October 1998
  • Yoshida, Masumi; Koshiyama, Masafumi; Konishi, Mitsunaga
  • European Journal of Obstetrics & Gynecology and Reproductive Biology, Vol. 81, Issue 1, p. 123-128
  • DOI: 10.1016/S0301-2115(98)00162-6

Similar records in DOepatents and OSTI.GOV collections: